Solid tumors account for approximately 90% of all types cancer. For many tumor types, the availability effective treatment options is limited and new targeted approaches that offer potential long-term survival are warranted. Antibody-drug conjugates (ADCs) a class drugs have emerged as promising therapeutic option shown significant clinical benefit in selected malignancies. ADCs highly drugs, c...